Millennium Management’s Royalty Pharma RPRX Stock Holding History

Millennium Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-459,300	Closed	-$14.3M	–	6265
2025 Q1	$14.3M	Buy	459,300 +325,500	+243%	+$10.3M	0.01%	1838
2024 Q4	$3.41M	Sell	133,800 -74,500	-36%	-$1.98M	﹤0.01%	3177
2024 Q3	$5.89M	Buy	208,300 +200,300	+2,504%	+$5.55M	﹤0.01%	2700
2024 Q2	$211K	Hold	8,000	–	–	﹤0.01%	5112
2024 Q1	$243K	Sell	8,000 -13,500	-63%	-$398K	﹤0.01%	5265
2023 Q4	$604K	Sell	21,500 -3,700	-15%	-$102K	﹤0.01%	4526
2023 Q3	$684K	Buy	+25,200	New	+$748K	﹤0.01%	4459
2022 Q3	–	Sell	-16,700	Closed	-$702K	–	7425
2022 Q2	$702K	Buy	+16,700	New	+$685K	﹤0.01%	4692
2021 Q4	–	Sell	-200,000	Closed	-$7.23M	–	7304
2021 Q3	$7.23M	Buy	200,000 +60,000	+43%	+$2.33M	﹤0.01%	2443
2021 Q2	$5.74M	Buy	140,000 +100,000	+250%	+$4.25M	﹤0.01%	2571
2021 Q1	$1.75M	Buy	+40,000	New	+$1.9M	﹤0.01%	3659

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management's RPRX Position: Q1 2026 in Review

Millennium Management sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 116,839 shares — an estimated $4.51M sold.

Millennium Management first reported a position in RPRX in Q2 2020 and held it in 22 quarters. The position peaked at $142M in Q1 2024. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Millennium Management reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 116,839 Royalty Pharma shares in Q1 2026, an estimated $4.51M.
Millennium Management first reported a position in Royalty Pharma in Q2 2020 and held it in 22 quarters.
Millennium Management's Royalty Pharma position peaked at $142M in Q1 2024.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.